FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer ...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee ...

MILAN--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its Phase 3 clinical trial, THRIVE-AA1. The presentation highlights THRIVE-AA1 study ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...

HOUSTON--(BUSINESS WIRE)--Tvardi Therapeutics, Inc. (“Tvardi”) will publicly present, for the first time, clinical results from the Phase 1 study of TTI-101, a STAT3 inhibitor, in relapsed/refractory ...

Rezolute, Inc., a company focused on treating hypoglycemia caused by hyperinsulinism, announced that its abstract for a Phase 3 study of its drug Ersodetug will be presented at ENDO 2025 in San ...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas ...

August 11, 2025 - Previous articles in this series have explored identification, preservation, collection, review and production of novel data sources, but I would be remiss if I left out the last, ...

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of ...

Factors Influencing Time From Diagnosis to Treatment of Breast Cancer and the Impact of Longer Waiting Time on Survival in Kathmandu Valley, Nepal: A Population-Based Study More women in P3 than P1 ...